

**Remarks**

Upon entry of the present amendment, claims 120-167 will be pending. Claims 1-119 have been canceled without prejudice or disclaimer. New claims 120-167 have been added. Support for claims 120-167 can be found throughout the specification and in the claims as originally filed. Thus, the amendment adds no new matter.

In the Response to the Restriction Requirement filed April 18, 2007, Applicants inadvertently failed to list claim 13 in the listing of the claims, as noted in the notice of non-compliant amendment dated June 20, 2007. Applicants apologize for this oversight. Claim 13 has been canceled.

In response to the Restriction Requirement mailed October 18, 2006, Applicants elect Group I directed to oligomeric compounds. Claims 120-167 read on Group I.

The Restriction Requirement further required an election of species. See Restriction Requirement at page 3. Applicants elect the species wherein the oligomeric compound is a gapped oligomeric compound, each of the first type of nucleosides are unsubstituted 2'-OCH<sub>3</sub> modified nucleosides and the second type of nucleosides are ribonucleosides. Applicants further elect for the species of internucleoside linkage for the first and second regions a mixture of phosphodiester and phosphorothioate internucleoside linkages. Claims 120 to 123, 127, 136 to 139, 143, 148 to 153, 155 to 162, and 164 to 167 read on the elected species.

**Conclusion**

Applicants believe that the foregoing constitutes a complete and full response to both the official action dated October 18, 2006 and the notice of non-compliant amendment dated June 20, 2007. An early and favorable action is accordingly, respectfully requested.

Respectfully submitted,

Date: November 20, 2007

/Jane E. Inglesse/  
Jane E. Inglesse, Ph.D.  
Registration No. 48,444

Woodcock Washburn LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439